Healius (ASX:HLS) has announced concerns to Australian Clinical Lab's (ACL) off-market takeover bid of a share exchange ratio of 0.74 ACL shares for every one Healius share, which is a discount of 4.2% to the price the day before the offer.
The Australian healthcare company noted some of the offer's deficiencies, including overly restrictive conditions and a lack of control premium.
Healius' largest shareholder, Perpetual Investment Management, called the proposal unattractive and unfavourable for Healius' shareholders, while Tanarra Capital stated ACL could not achieve 90% ownership.
Healius' board will consider future merger proposals but reiterated its "take no action" advice regarding ACL's offer.